Jasper Therapeutics Statistics
Share Statistics
Jasper Therapeutics has 16.47M shares outstanding. The number of shares has increased by -86.46% in one year.
| Shares Outstanding | 16.47M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.13% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 11.23M |
| Failed to Deliver (FTD) Shares | 606 |
| FTD / Avg. Volume | 0.22% |
Short Selling Information
The latest short interest is 1.76M, so 11.7% of the outstanding shares have been sold short.
| Short Interest | 1.76M |
| Short % of Shares Out | 11.7% |
| Short % of Float | 15.59% |
| Short Ratio (days to cover) | 4.94 |
Valuation Ratios
The PE ratio is -1.28 and the forward PE ratio is -5.28.
| PE Ratio | -1.28 |
| Forward PE | -5.28 |
| PS Ratio | 0 |
| Forward PS | 76.8 |
| PB Ratio | 1.05 |
| P/FCF Ratio | -1.57 |
| PEG Ratio | n/a |
Enterprise Valuation
Jasper Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 7.19, with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.19 |
| Quick Ratio | 7.19 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 1.22 |
| Cash Flow / Debt | -53.57 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.82% and return on capital (ROIC) is -82.69%.
| Return on Equity (ROE) | -0.82% |
| Return on Assets (ROA) | -0.68% |
| Return on Capital (ROIC) | -82.69% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.43M |
| Employee Count | 45 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -1.63M |
| Effective Tax Rate | 0.02 |
Stock Price Statistics
The stock price has increased by 323.76% in the last 52 weeks. The beta is 2.2, so Jasper Therapeutics 's price volatility has been higher than the market average.
| Beta | 2.2 |
| 52-Week Price Change | 323.76% |
| 50-Day Moving Average | 20.85 |
| 200-Day Moving Average | 22.05 |
| Relative Strength Index (RSI) | 42.47 |
| Average Volume (20 Days) | 278.47K |
Income Statement
In the last 12 months, Jasper Therapeutics had revenue of $0 and earned -$64.47M in profits. Earnings per share was $-6.18.
| Revenue | 0 |
| Gross Profit | -1.11M |
| Operating Income | -68.86M |
| Net Income | -64.47M |
| EBITDA | -64.98M |
| EBIT | - |
| Earnings Per Share (EPS) | -6.18 |
Balance Sheet
The company has $86.89M in cash and $2.79M in debt, giving a net cash position of $84.10M.
| Cash & Cash Equivalents | 86.89M |
| Total Debt | 2.79M |
| Net Cash | 84.10M |
| Retained Earnings | -169.60M |
| Total Assets | 99.41M |
| Working Capital | 82.35M |
Cash Flow
In the last 12 months, operating cash flow was -$52.07M and capital expenditures -$267.00K, giving a free cash flow of -$52.33M.
| Operating Cash Flow | -52.07M |
| Capital Expenditures | -267.00K |
| Free Cash Flow | -52.33M |
| FCF Per Share | -5.01 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
JSPR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -30.13% |
| FCF Yield | -15.5% |
Analyst Forecast
The average price target for JSPR is $69, which is 236.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $69 |
| Price Target Difference | 236.4% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Stock Splits
The last stock split was on Jan 4, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Jan 4, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | 7.7 |
| Piotroski F-Score | 1 |